Study of Zanzalintinib for recurring meningioma
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a drug called Zanzalintinib for people with meningioma that has come back or grown despite past treatments. It aims to see if the drug can stop or slow tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed meningioma (grade 1, 2, or 3).
- Your tumor has grown or come back after standard treatments like surgery or radiation.
- You have had at least one round of radiation therapy for meningioma (unless it's not safe for you).
- A recent MRI or CT scan shows your tumor has grown in the last 6 months.
- You are able to care for yourself (Karnofsky score of 60% or higher).
- Your organs (like kidneys and liver) are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies cabozantinib, a targeted pill medicine, for meningioma that has come back or is getting worse after standard treatment like surgery or radiation. It aims to shrink tumors and slow progression when other options may have limited benefit.
This study tests a new drug called JZP3507 for people with meningioma (a type of brain tumor, grades 2 or 3) that has come back or grown despite previous treatment. The goal is to see if this medication can slow or shrink the tumor.
This trial tests a new drug, zanzalintinib, for people with adenoid cystic carcinoma that has come back or spread and can't be treated with local therapy. The drug may help slow or stop the cancer's growth.
This trial tests a new drug called zanzalintinib for people with advanced or metastatic bone sarcomas that have not responded to standard treatments. It aims to see if the drug can help shrink or slow the growth of these tumors.
This trial tests a new drug called zanzalintinib in children and teenagers with solid tumors that have come back or not responded to treatment. The goal is to see if the drug is safe and helpful for these patients.
This trial tests a new oral medication called zanzalintinib for adults with a rare type of tumor called pheochromocytoma or paraganglioma that has spread or cannot be removed with surgery. The goal is to see if this drug can slow or stop the tumor from growing, and to evaluate its safety.
Hear when a new Meningioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.